Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nutritional status and apatinib outcomes in advanced malignant tumors
ChiCTR1800014510Phase 4Completed
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jan 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in Non-hematologic malignancy, sponsored by Zhejiang Cancer Hospital. Primary endpoints: Nutritional status, Safety and 1 more. Started Jan 2018; status: completed.
02
Drugs
Rivoceranib
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on ChiCTR1800014510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800014510.